查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球最小残留疾病检测市场：按技术(PCR,流式细胞仪,NGS),应用(白血病,淋巴瘤,实体瘤),用户(医院和专科诊所,诊断实验室,研究和教育机构),地区预测到2027
市场调查报告书
商品编码
1173528

全球最小残留疾病检测市场：按技术(PCR,流式细胞仪,NGS),应用(白血病,淋巴瘤,实体瘤),用户(医院和专科诊所,诊断实验室,研究和教育机构),地区预测到2027

Minimal Residual Disease Testing Market by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User(Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast -2027
出版日期: | 出版商: MarketsandMarkets | 英文 175 Pages | 订单完成后即时交付

价格
简介目录

全球最小残留病检测市场规模预计到 2022 年将达到 12 亿美元，到 2027 年将达到 23 亿美元，在预测期内保持 14.0% 的复合年增长率。

在市场增长的背景下，癌症和恶性血液肿瘤患者的数量增加，政府的癌症意识活动增加，公司之间的合作和伙伴关係加强。

按技术划分，PCR 细分市场在 2021 年的增长率最高。 因素包括设备和检测试剂盒的易用性和灵敏度。

从应用来看，恶性血液病领域在 2021 年的 CAGR 最高。 白血病、淋巴瘤等疾病的发病率上升以及对患有这些疾病的患者进行持续监测的意识是推动市场增长的主要因素。

按地区划分，亚太地区预计将以最高的复合年增长率增长。 造成这种情况的主要原因是医疗保健基础设施的改善、大量患者的存在、对该地区主要参与者的兴趣增加、政府努力提高疾病检测意识、医疗保健支出持续增加，其中包括医院的增加和临床诊断实验室，并加强印度、中国和日本的诊断程序研究基础设施。

本报告分析了全球微小残留病检测市场，包括市场的基本结构和最新发展、主要市场驱动因素和製约因素，以及按技术、应用、最终用户和地区划分的市场趋势。前景、状态市场竞争，以及主要参与者的概况。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 介绍
  • 市场动态
    • 司机
    • 约束因素
    • 机会
    • 任务
  • 价格分析
  • 专利分析
  • 价值链分析
  • 供应链分析
  • 生态系统/市场分析
  • 波特的五力分析
  • 监管分析
  • 贸易分析
  • 技术分析
  • 主要会议和活动 (2022-2023)
  • 影响客户业务的趋势/颠覆
  • 主要利益相关者和采购标准
  • 案例研究分析

第 6 章最小残留病检测市场：按技术分类

  • 介绍
  • 聚合□炼式反应 (PCR)
  • 下一代测序 (NGN)
  • 流式细胞仪
  • 其他技术

第 7 章最小残留病检测市场：按应用

  • 介绍
  • 恶性血液肿瘤
    • 白血病
    • 淋巴瘤
  • 实体瘤
  • 其他用途

第 8 章最小残留病检测市场：最终用户

  • 介绍
  • 医院和专科诊所
  • 诊断实验室
  • 教育和研究机构
  • 其他最终用户

第 9 章最小残留病检测市场：按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太国家
  • 拉丁美洲
  • 中东和非洲

第10章竞争格局

  • 概览
  • 主要公司/有影响力公司的战略
  • 主要公司的收入份额分析
  • 市场份额分析
  • 公司评估象限
  • 初创公司/中小企业的竞争领导力图谱(2021 年)
  • 按产品和地区进行足迹分析
  • 竞争场景
    • 产品发布
    • 资本交易

第11章公司简介

  • 主要公司
    • ADAPTIVE BIOTECHNOLOGIES
    • ARCHERDX (INVITAE CORPORATION)
    • ASURAGEN, INC.
    • BIO-RAD LABORATORIES, INC.
    • F. HOFFMANN-LA ROCHE AG
    • GUARDANT HEALTH, INC.
    • MOLECULARMD (ICON PLC子会社)
    • INVIVOSCRIBE, INC.
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • NATERA, INC.
    • SYSMEX CORPORATION
  • 其他企业
    • NEOGENOMICS LABORATORIES
    • OPKO HEALTH, INC.
    • GENETRON HEALTH
    • QUEST DIAGNOSTICS, INC.
    • ARUP LABORATORIES INC.
    • MISSION BIO, INC.
    • CERGENTIS B.V.

第12章 附录

简介目录
Product Code: MD 8516

The global minimal residual disease testing market is valued at an estimated USD 1.2 Billion in 2022 and is projected to reach USD 2.3 Billion by 2027, at a CAGR of 14.0% during the forecast period. Market growth is driven by rise in the number of patients with cancer and hematological malignancies, growing awareness drives regarding cancer by government, and increasing collaborations and partnerships between companies.

"The PCR segment accounted for the highest growth rate in the minimal residual disease testing market, by technology, during the forecast period"

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). In 2021, the PCR segment accounted for the highest growth rate in the minimal residual disease testing market. Device being easy to use, easy accessibility of assay kits, and a good sensitivity are the major factors contributing the large share of this segment.

"Hematological Malignancies applications segment accounted for the highest CAGR"

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

"Asia Pacific: The fastest-growing region minimal residual disease testing market"

The global minimal residual disease testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific minimal residual disease testing market is estimated to grow at the highest CAGR during the forecast period, primarily due to improving healthcare infrastructure, the presence of a large pool of patient population, the rising focus of key players in the region, government efforts to increase awareness about the detection of diseases, continuously rising healthcare expenditures, an increasing number of hospitals & clinical diagnostic laboratories in India and China, and the strengthening research base for diagnostic procedures across India, China, and Japan.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, Latin America -9%, and the Middle East & Africa - 3%

Lists of Companies Profiled in the Report:

  • Labcorp Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Guardant Health (US)
  • Sysmex Corporation (Japan)
  • NeoGenomics Laboratories, Inc. (US)
  • Adaptive Biotechnologies Corporation (US)
  • ArcherDX, Inc. (US)
  • Asuragen Inc. (US)
  • Arup Laboratories Inc. (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Cergentis B.V. (Netherlands)
  • Molecular MD (ICON plc) (Ireland)
  • Invivoscribe, Inc. (US)
  • Mission Bio, Inc. (US)
  • Natera, Inc. (US)
  • Opko Health, Inc. (US)
  • Quest Diagnostics (US)
  • Genetron Health (China)

Research Coverage:

This report provides a detailed picture of the global minimal residual disease testing market. It aims at estimating the size and future growth potential of the market across different segments, such as technology, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall minimal residual disease testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKETS COVERED
    • 1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
    • FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET
  • 4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
    • FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027
  • 4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027
    • FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2027
  • 4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
    • FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
  • 4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of hematological malignancies
    • TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
      • 5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
      • 5.2.1.3 Increasing cancer awareness initiatives by global health organizations
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests
      • 5.2.2.2 High cost of minimal residual disease testing kits
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries
    • TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unclear reimbursement scenario and policies for patients
  • 5.3 PRICING ANALYSIS
    • TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)
  • 5.4 PATENT ANALYSIS
    • FIGURE 18 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
    • 5.4.1 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM/MARKET ANALYSIS
    • FIGURE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM/MARKET ANALYSIS
    • TABLE 5 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 REGULATORY ANALYSIS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
    • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.9.3.2 Japan
    • TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 Brazil
      • 5.9.4.2 Mexico
    • 5.9.5 MIDDLE EAST
    • 5.9.6 AFRICA
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
    • TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY, 2017-2021 (USD MILLION)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 16 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS
    • FIGURE 22 REVENUE SHIFT IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS
    • TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
    • 5.14.2 BUYING CRITERIA
    • FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
    • TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
  • 5.15 CASE STUDY ANALYSIS

6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 6.2 POLYMERASE CHAIN REACTION
    • 6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
    • TABLE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 NEXT-GENERATION SEQUENCING
    • 6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET
    • TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 FLOW CYTOMETRY
    • 6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH
    • TABLE 22 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2020-2027 (USD MILLION)
  • 6.5 OTHER TECHNOLOGIES
    • TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)

7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 HEMATOLOGICAL MALIGNANCIES
    • TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020-2027 (USD MILLION)
    • 7.2.1 LEUKEMIA
    • TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020-2027 (USD MILLION)
      • 7.2.1.1 Myeloid leukemia
        • 7.2.1.1.1 High prevalence of AML in adults to support growth
    • TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
      • 7.2.1.2 Lymphocytic leukemia
        • 7.2.1.2.1 High incidence of ALL in children to drive market
    • TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2020-2027 (USD MILLION)
      • 7.2.1.3 Other leukemias
    • TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 LYMPHOMA
    • TABLE 32 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 33 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020-2027 (USD MILLION)
      • 7.2.2.1 Non-Hodgkin lymphoma
        • 7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
    • TABLE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
      • 7.2.2.2 Hodgkin lymphoma
        • 7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing
    • TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 SOLID TUMORS
    • 7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
    • TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 OTHER APPLICATIONS
    • TABLE 37 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)

8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 38 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 8.2 HOSPITALS & SPECIALTY CLINICS
    • 8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
    • TABLE 39 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 DIAGNOSTIC LABORATORIES
    • 8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
    • TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 ACADEMIC & RESEARCH INSTITUTES
    • 8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
    • TABLE 41 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 OTHER END USERS
    • TABLE 42 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 43 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
    • TABLE 44 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 46 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Increasing prevalence of cancer to drive market
    • TABLE 48 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 49 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 50 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Availability of various cancer screening programs to support market growth
    • TABLE 51 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 52 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 53 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020-2035
    • TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 56 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 58 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Government support for research funding to support MRD testing market
    • TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 61 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 62 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Increasing number of diagnostic laboratories to propel market growth
    • TABLE 63 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 64 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 65 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Rising R&D expenditure in France to drive market
    • TABLE 66 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 67 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 68 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Favorable funding scenario to drive market
    • TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 70 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 71 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 72 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Consolidation of laboratories in Spain to support market growth
    • TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 74 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 75 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 76 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 77 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 78 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 26 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
    • TABLE 79 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Growing public access to advanced healthcare facilities to drive market
    • TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 85 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 86 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Universal healthcare reimbursement policy to support market growth
    • TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
    • TABLE 88 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 89 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 90 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Increasing private and public investments in healthcare system to drive market
    • TABLE 91 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 92 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 93 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019
    • TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 96 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 97 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
    • TABLE 98 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 99 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 100 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
    • TABLE 101 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 102 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
    • TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • 10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • 10.4 MARKET SHARE ANALYSIS
    • FIGURE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER (2021)
    • TABLE 105 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
  • 10.5 COMPANY EVALUATION QUADRANT
    • 10.5.1 LIST OF EVALUATED VENDORS
    • 10.5.2 STARS
    • 10.5.3 EMERGING LEADERS
    • 10.5.4 PERVASIVE PLAYERS
    • 10.5.5 PARTICIPANTS
    • FIGURE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021
  • 10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021)
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 STARTING BLOCKS
    • 10.6.3 RESPONSIVE COMPANIES
    • 10.6.4 DYNAMIC COMPANIES
    • FIGURE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
  • 10.7 COMPETITIVE BENCHMARKING
    • 10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
    • FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
    • TABLE 106 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 107 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES
    • TABLE 108 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 10.8 COMPETITIVE SCENARIO
    • 10.8.1 PRODUCT LAUNCHES
    • TABLE 109 KEY PRODUCT LAUNCHES
    • 10.8.2 DEALS
    • TABLE 110 KEY DEALS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)**
    • 11.1.1 ADAPTIVE BIOTECHNOLOGIES
    • TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
    • 11.1.2 ARCHERDX (INVITAE CORPORATION)
    • TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW
    • FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)
    • 11.1.3 ASURAGEN, INC.
    • TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW
    • 11.1.4 BIO-RAD LABORATORIES, INC.
    • TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 11.1.5 F. HOFFMANN-LA ROCHE AG
    • TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
    • 11.1.6 GUARDANT HEALTH, INC.
    • TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
    • FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
    • 11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
    • TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW
    • FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)
    • 11.1.8 INVIVOSCRIBE, INC.
    • TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
    • 11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
    • 11.1.10 NATERA, INC.
    • TABLE 120 NATERA, INC.: BUSINESS OVERVIEW
    • FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)
    • 11.1.11 SYSMEX CORPORATION
    • TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
  • 11.2 OTHER PLAYERS
    • 11.2.1 NEOGENOMICS LABORATORIES
    • 11.2.2 OPKO HEALTH, INC.
    • 11.2.3 GENETRON HEALTH
    • 11.2.4 QUEST DIAGNOSTICS, INC.
    • 11.2.5 ARUP LABORATORIES INC.
    • 11.2.6 MISSION BIO, INC.
    • 11.2.7 CERGENTIS B.V.
  • *Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS